Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide

Bone Marrow Transplantation volume 54, pages 1164–1167 (2019)Cite this article

Subjects

Abstract

We propose to test whether the new refined Minnesota risk score, which represents a new tool for acute Graft-versus-Host-Disease (aGVHD) grading, may be useful to predict the final outcome of patients with aGVHD after haploidentical stem cell transplantation (Haplo-SCT) with post-transplant cyclophosphamide (PT-Cy). Hundred consecutive patients with grade 2–4 aGVHD were included. Twenty-two percent of the patients had high-risk (HR) aGVHD and had a lower chance to respond at day 28: 41% of non-responders (NR) were in the HR vs 13% in the standard-risk (SR) group (p = 0.003). By multivariate analysis, grade 3–4 aGVHD according to the traditional Keystone classification was the main independent predictor of non-response to front-line treatment at day 28, while HR aGVHD by the new refined Minnesota score remained the main independent variable associated with adverse NRM and OS. The new Minnesota refined risk score is a useful tool to predict the outcome of patients with aGVHD after Haplo-SCT with PT-Cy. Due to the few patients exchanging between categories in the two classifications, it is not possible to discriminate which system better predicts the outcome of patients with aGVHD in the setting of Haplo-SCT. Extending these preliminary observations to a larger cohort is warranted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol. 2016;34:3141–9.

    Article  CAS  Google Scholar 

  2. Castagna L, Bramanti S, Furst S, Giordano L, Crocchiolo R, Sarina B, et al. Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant. 2014;49:1475–80.

    Article  CAS  Google Scholar 

  3. Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Widjenes J, et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation. 1995;60:939–42.

    Article  CAS  Google Scholar 

  4. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C. et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150–63.

    Article  Google Scholar 

  5. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.

    Article  CAS  Google Scholar 

  6. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.

    CAS  PubMed  Google Scholar 

  7. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–64.

    Article  CAS  Google Scholar 

  8. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21:761–7.

    Article  Google Scholar 

  9. Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A, et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant. 2012;47:125–31.

    Article  CAS  Google Scholar 

  10. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010;115:5412–7.

    Article  CAS  Google Scholar 

  11. Levine JE, Harris AC, Taylor A, et al. A biomarker-based grading system at onset of GVHD predicts TRM better than the modified Glucksberg Gradyng System. Blood. 2013;122:145.

    Google Scholar 

  12. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2:e21–9.

    Article  Google Scholar 

  13. Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, et al. MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD. Blood. 2018;131:2846–55.

    Article  CAS  Google Scholar 

  14. Kanakry CG, Bakoyannis G, Perkins SM, McCurdy SR, Vulic A, Warren EH, et al. Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica. 2017;102:932–40.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy

    Jacopo Mariotti, Stefania Bramanti, Barbara Sarina, Carmelo Carlo-Stella, Armando Santoro & Luca Castagna

  2. Department of Hematology, Transplantation Program, Marseille, France

    Angela Granata, Raynier Devillier, Sabine Furst, Samia Harbi, Faezeh Legrand, Catherine Faucher, Pierre Jean Weiller & Didier Blaise

  3. Cell Therapy Unit, Institut Paoli Calmettes, Marseille, France

    Christian Chabannon

  4. Aix-Marseille Université, Marseille, France

    Christian Chabannon & Didier Blaise

  5. Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France

    Christian Chabannon & Didier Blaise

  6. Humanitas University, Humanitas Clinical and Research Hospital, Rozzano, Italy

    Carmelo Carlo-Stella & Armando Santoro

Authors
  1. Jacopo Mariotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angela Granata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefania Bramanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raynier Devillier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sabine Furst
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Barbara Sarina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Samia Harbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Faezeh Legrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Catherine Faucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pierre Jean Weiller
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Christian Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Carmelo Carlo-Stella
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Armando Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Didier Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Luca Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacopo Mariotti.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mariotti, J., Granata, A., Bramanti, S. et al. The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide. Bone Marrow Transplant 54, 1164–1167 (2019). https://doi.org/10.1038/s41409-019-0453-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0453-0

Search

Advanced search

Quick links